STAT
U.S. center-left (health and life-sciences trade news)
Background
STAT launched in late 2015. John and Linda Henry started it as a test of whether readers would pay for in-depth life-sciences journalism, two years after Henry bought The Boston Globe from The New York Times. It is based in Boston and has reporters in Washington and other cities. It built a business on a paywalled STAT+ tier, newsletters, events and licensing, with subscriptions as the main revenue source. Over time it became a go-to source for industry readers, including drug makers, investors, researchers and regulators, with a focus on the FDA, NIH, biotech and health policy. The Boston Globe reported that STAT laid off 11 employees in December 2024, a sign of the financial pressure on niche news outlets. In Trump's second term, its recent coverage includes the HHS leadership shake-up, the proposed 12% HHS budget cut, federal worker tensions, and a plan to expand access to peptide drugs that Kennedy favors. It reports these developments mainly with a news focus and cites federal employees and experts. The coverage often highlights risks to public health and scientific norms, which reads as skeptical of administration health policy, but I did not find a systematic review rating its bias. Media Bias/Fact Check evaluates the outlet, though I did not retrieve its rating.
Sources
- Stat (website) - Wikipedia
- Health and medicine publication STAT lays off 11 employees - The Boston Globe
- Stat Tops 30,000 Subscribers, Nears $20 Million in Revenue - Adweek
- Boston Globe Media Partners' Stat launches a $299-a-year membership program - Digiday
- STAT Marks 10 Years of Reporting from the Frontiers of Health and Medicine
- Stat (News) - Bias and Credibility - Media Bias/Fact Check
- Trump administration advances plan for peptide drugs favored by RFK Jr. - STAT
- Trump health budget offers investments in MAHA, cuts to HHS, NIH - STAT
Profile compiled 2026-10-21; refreshed when ownership, funding, or the administration changes.